相似文献
1
Immune therapy for breast cancer in 2010-hype or hope?
Curr Oncol. 2011 Jan;18(1):e9-e18. doi: 10.3747/co.v18i1.623.
2
Immunotherapeutic approaches for the treatment of breast cancer.
J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):353-65. doi: 10.1023/a:1018714300217.
3
An efficient or methodical review of immunotherapy against breast cancer.
J Biochem Mol Toxicol. 2019 Aug;33(8):e22339. doi: 10.1002/jbt.22339. Epub 2019 Jun 3.
4
[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Zentralbl Gynakol. 1999;121(4):190-5.
5
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5.
6
Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
Curr Probl Cancer. 2016 Mar-Aug;40(2-4):151-162. doi: 10.1016/j.currproblcancer.2016.09.009. Epub 2016 Sep 26.
7
Progress in Vaccine Therapies for Breast Cancer.
Adv Exp Med Biol. 2017;1026:315-330. doi: 10.1007/978-981-10-6020-5_15.
8
Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.
Expert Rev Clin Immunol. 2014 Jul;10(7):927-61. doi: 10.1586/1744666X.2014.916211. Epub 2014 May 28.
9
Next generation of immunotherapy for melanoma.
J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423.
10
Immune Checkpoint Blockade in Breast Cancer Therapy.
Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.
引用本文的文献
1
Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.
Nano Res. 2025 Jul;18(7). doi: 10.26599/nr.2025.94907534. Epub 2025 May 22.
2
Bridging molecular insights and clinical application: non-coding RNAs, targeted drug delivery, and metastatic breast cancer therapy.
Discov Oncol. 2025 Jul 26;16(1):1413. doi: 10.1007/s12672-025-03090-1.
3
Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics.
Int J Mol Sci. 2021 May 30;22(11):5878. doi: 10.3390/ijms22115878.
4
Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan.
Eur J Breast Health. 2018 Oct 1;14(4):199-204. doi: 10.5152/ejbh.2018.4048. eCollection 2018 Oct.
5
Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer.
Neoplasia. 2015 Apr;17(4):348-57. doi: 10.1016/j.neo.2015.02.006.
6
Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China.
Int J Clin Exp Pathol. 2014 Aug 15;7(9):6262-9. eCollection 2014.
7
Dracorhodin perchlorate induced human breast cancer MCF-7 apoptosis through mitochondrial pathways.
Int J Med Sci. 2013 Jul 7;10(9):1149-56. doi: 10.7150/ijms.6275. Print 2013.
8
T cell coinhibition and immunotherapy in human breast cancer.
Discov Med. 2012 Oct;14(77):229-36.
9
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.
本文引用的文献
1
An autoimmune-mediated strategy for prophylactic breast cancer vaccination.
Nat Med. 2010 Jul;16(7):799-803. doi: 10.1038/nm.2161. Epub 2010 May 30.
2
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.
Clin Cancer Res. 2009 Sep 15;15(18):5937-44. doi: 10.1158/1078-0432.CCR-08-3282. Epub 2009 Sep 1.
3
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Breast Cancer Res Treat. 2009 Sep;117(1):83-9. doi: 10.1007/s10549-008-0251-7. Epub 2008 Dec 3.
4
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.
5
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
J Clin Oncol. 2007 Aug 20;25(24):3680-7. doi: 10.1200/JCO.2006.10.5718.
6
Development of vaccines for high-risk ductal carcinoma in situ of the breast.
Cancer Res. 2007 Jul 15;67(14):6531-4. doi: 10.1158/0008-5472.CAN-07-0878.
7
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Cancer Immunol Immunother. 2007 Aug;56(8):1285-97. doi: 10.1007/s00262-007-0279-2. Epub 2007 Jan 31.
8
Immunotherapy for renal cell cancer.
J Clin Oncol. 2006 Dec 10;24(35):5576-83. doi: 10.1200/JCO.2006.08.3774.
9
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy.
Mol Cancer Ther. 2006 Aug;5(8):2106-14. doi: 10.1158/1535-7163.MCT-06-0158.
10
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
J Clin Oncol. 2006 Jun 20;24(18):2786-92. doi: 10.1200/JCO.2005.04.1764.
Zotero 插件